269 related articles for article (PubMed ID: 25482183)
1. RASSF6 exhibits promoter hypermethylation in metastatic melanoma and inhibits invasion in melanoma cells.
Mezzanotte JJ; Hill V; Schmidt ML; Shinawi T; Tommasi S; Krex D; Schackert G; Pfeifer GP; Latif F; Clark GJ
Epigenetics; 2014 Nov; 9(11):1496-503. PubMed ID: 25482183
[TBL] [Abstract][Full Text] [Related]
2. Decreased expression and frequent promoter hypermethylation of RASSF2 and RASSF6 correlate with malignant progression and poor prognosis of gastric cardia adenocarcinoma.
Guo W; Dong Z; Guo Y; Shen S; Guo X; Kuang G; Yang Z
Mol Carcinog; 2016 Nov; 55(11):1655-1666. PubMed ID: 26456015
[TBL] [Abstract][Full Text] [Related]
3. RASSF6 is a novel member of the RASSF family of tumor suppressors.
Allen NP; Donninger H; Vos MD; Eckfeld K; Hesson L; Gordon L; Birrer MJ; Latif F; Clark GJ
Oncogene; 2007 Sep; 26(42):6203-11. PubMed ID: 17404571
[TBL] [Abstract][Full Text] [Related]
4. The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma.
Djos A; Martinsson T; Kogner P; Carén H
Mol Cancer; 2012 Jun; 11():40. PubMed ID: 22695170
[TBL] [Abstract][Full Text] [Related]
5. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
[TBL] [Abstract][Full Text] [Related]
6. DNA hypermethylation of tumor suppressor genes RASSF6 and RASSF10 as independent prognostic factors in adult acute lymphoblastic leukemia.
Younesian S; Shahkarami S; Ghaffari P; Alizadeh S; Mehrasa R; Ghavamzadeh A; Ghaffari SH
Leuk Res; 2017 Oct; 61():33-38. PubMed ID: 28869817
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic inactivation of the RAS-effector gene RASSF2 in lung cancers.
Kaira K; Sunaga N; Tomizawa Y; Yanagitani N; Ishizuka T; Saito R; Nakajima T; Mori M
Int J Oncol; 2007 Jul; 31(1):169-73. PubMed ID: 17549418
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of RASSF6 promotes breast cancer growth and chemoresistance through regulation of Hippo signaling.
He Z; Zhao TT; Jin F; Li JG; Xu YY; Dong HT; Liu Q; Xing P; Zhu GL; Xu H; Miao ZF
Biochem Biophys Res Commun; 2018 Sep; 503(4):2340-2347. PubMed ID: 29964010
[TBL] [Abstract][Full Text] [Related]
9. Frequent silencing of RASSF1A via promoter methylation in follicular thyroid hyperplasia: a potential early epigenetic susceptibility event in thyroid carcinogenesis.
Brown TC; Juhlin CC; Healy JM; Prasad ML; Korah R; Carling T
JAMA Surg; 2014 Nov; 149(11):1146-52. PubMed ID: 25229773
[TBL] [Abstract][Full Text] [Related]
10. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
[TBL] [Abstract][Full Text] [Related]
11. Promoter hypermethylation profiling of distant breast cancer metastases.
Schrijver WA; Jiwa LS; van Diest PJ; Moelans CB
Breast Cancer Res Treat; 2015 May; 151(1):41-55. PubMed ID: 25841351
[TBL] [Abstract][Full Text] [Related]
12. RASSF10 promoter hypermethylation is frequent in malignant melanoma of the skin but uncommon in nevus cell nevi.
Helmbold P; Richter AM; Walesch S; Skorokhod A; Marsch WCh; Enk A; Dammann RH
J Invest Dermatol; 2012 Mar; 132(3 Pt 1):687-94. PubMed ID: 22113481
[TBL] [Abstract][Full Text] [Related]
13. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
Karreth FA; DeNicola GM; Winter SP; Tuveson DA
Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
[TBL] [Abstract][Full Text] [Related]
14. The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias.
Hesson LB; Dunwell TL; Cooper WN; Catchpoole D; Brini AT; Chiaramonte R; Griffiths M; Chalmers AD; Maher ER; Latif F
Mol Cancer; 2009 Jul; 8():42. PubMed ID: 19570220
[TBL] [Abstract][Full Text] [Related]
15. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
16. Aberrant methylation of RASSF4/AD037 in nasopharyngeal carcinoma.
Chow LS; Lo KW; Kwong J; Wong AY; Huang DP
Oncol Rep; 2004 Oct; 12(4):781-7. PubMed ID: 15375500
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.
Spugnardi M; Tommasi S; Dammann R; Pfeifer GP; Hoon DS
Cancer Res; 2003 Apr; 63(7):1639-43. PubMed ID: 12670917
[TBL] [Abstract][Full Text] [Related]
18. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
19. Decreased level of RASSF6 in sporadic colorectal cancer and its anti-tumor effects both in vitro and in vivo.
Chen E; Yang F; He H; Lei L; Liu R; Du L; Dong J; Wang M; Yang J
Oncotarget; 2016 Apr; 7(15):19813-23. PubMed ID: 27009808
[TBL] [Abstract][Full Text] [Related]
20. Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases.
Miranda E; Bianchi P; Destro A; Morenghi E; Malesci A; Santoro A; Laghi L; Roncalli M
Cancer; 2013 Jan; 119(2):266-76. PubMed ID: 22786759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]